Piramal Pharma reported ₹8,869 Cr revenue, ₹1,135 Cr EBITDA, and a ₹325.94 Cr net loss amid market headwinds.

The company invested ₹890 Cr and US$90M in advanced therapies, boosting growth prospects.

Operational excellence drove 22.6% emissions cut & 41% renewable energy, with advancing digital transformation.